Long-acting antituberculous therapeutic nanoparticles target macrophage endosomes

Benson J Edagwa, Dongwei Guo, Pavan Puligujja, Han Chen, JoEllyn M McMillan, Xinming Liu, Howard Eliot Gendelman, Prabagaran Narayanasamy

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Eradication of Mycobacterium tuberculosis (MTB) infection requires daily administration of combinations of rifampin (RIF), isoniazid [isonicotinylhydrazine (INH)], pyrazinamide, and ethambutol, among other drug therapies. To facilitate and optimize MTB therapeutic selections, a mononuclear phagocyte (MP; monocyte, macrophage, and dendritic cell)-targeted drug delivery strategy was developed. Long-acting nanoformulations of RIF and an INH derivative, pentenyl-INH (INHP), were prepared, and their physicochemical properties were evaluated. This included the evaluation of MP particle uptake and retention, cell viability, and antimicrobial efficacy. Drug levels reached 6 μg/10 6 cells in human monocyte-derived macrophages (MDMs) for nanoparticle treatments compared with 0.1 μg/10 6 cells for native drugs. High RIF and INHP levels were retained in MDM for >15 d following nanoparticle loading. Rapid loss of native drugs was observed in cells and culture fluids within 24 h. Antimicrobial activities were determined against Mycobacterium smegmatis (M. smegmatis). Coadministration of nanoformulated RIF and INHP provided a 6-fold increase in therapeutic efficacy compared with equivalent concentrations of native drugs. Notably, nanoformulated RIF and INHP were found to be localized in recycling and late MDM endosomal compartments. These were the same compartments that contained the pathogen. Our results demonstrate the potential of antimicrobial nanomedicines to simplify MTB drug regimens.

Original languageEnglish (US)
Pages (from-to)5071-5082
Number of pages12
JournalFASEB Journal
Volume28
Issue number12
DOIs
StatePublished - Dec 1 2014

Fingerprint

Macrophages
Endosomes
Rifampin
Nanoparticles
Derivatives
Mycobacterium tuberculosis
Pharmaceutical Preparations
Medical nanotechnology
Drug therapy
Therapeutics
Pyrazinamide
Ethambutol
Nanomedicine
Mycobacterium smegmatis
Isoniazid
Pathogens
Mycobacterium Infections
Recycling
Phagocytes
Dendritic Cells

Keywords

  • Immunoisolation
  • MDM
  • Mycobacterium smegmatis
  • Mycobacterium tuberculosis
  • Subcellular trafficking

ASJC Scopus subject areas

  • Biotechnology
  • Biochemistry
  • Molecular Biology
  • Genetics

Cite this

Long-acting antituberculous therapeutic nanoparticles target macrophage endosomes. / Edagwa, Benson J; Guo, Dongwei; Puligujja, Pavan; Chen, Han; McMillan, JoEllyn M; Liu, Xinming; Gendelman, Howard Eliot; Narayanasamy, Prabagaran.

In: FASEB Journal, Vol. 28, No. 12, 01.12.2014, p. 5071-5082.

Research output: Contribution to journalArticle

@article{d29e2bb63e6b4f63b7be864702669fe4,
title = "Long-acting antituberculous therapeutic nanoparticles target macrophage endosomes",
abstract = "Eradication of Mycobacterium tuberculosis (MTB) infection requires daily administration of combinations of rifampin (RIF), isoniazid [isonicotinylhydrazine (INH)], pyrazinamide, and ethambutol, among other drug therapies. To facilitate and optimize MTB therapeutic selections, a mononuclear phagocyte (MP; monocyte, macrophage, and dendritic cell)-targeted drug delivery strategy was developed. Long-acting nanoformulations of RIF and an INH derivative, pentenyl-INH (INHP), were prepared, and their physicochemical properties were evaluated. This included the evaluation of MP particle uptake and retention, cell viability, and antimicrobial efficacy. Drug levels reached 6 μg/10 6 cells in human monocyte-derived macrophages (MDMs) for nanoparticle treatments compared with 0.1 μg/10 6 cells for native drugs. High RIF and INHP levels were retained in MDM for >15 d following nanoparticle loading. Rapid loss of native drugs was observed in cells and culture fluids within 24 h. Antimicrobial activities were determined against Mycobacterium smegmatis (M. smegmatis). Coadministration of nanoformulated RIF and INHP provided a 6-fold increase in therapeutic efficacy compared with equivalent concentrations of native drugs. Notably, nanoformulated RIF and INHP were found to be localized in recycling and late MDM endosomal compartments. These were the same compartments that contained the pathogen. Our results demonstrate the potential of antimicrobial nanomedicines to simplify MTB drug regimens.",
keywords = "Immunoisolation, MDM, Mycobacterium smegmatis, Mycobacterium tuberculosis, Subcellular trafficking",
author = "Edagwa, {Benson J} and Dongwei Guo and Pavan Puligujja and Han Chen and McMillan, {JoEllyn M} and Xinming Liu and Gendelman, {Howard Eliot} and Prabagaran Narayanasamy",
year = "2014",
month = "12",
day = "1",
doi = "10.1096/fj.14-255786",
language = "English (US)",
volume = "28",
pages = "5071--5082",
journal = "FASEB Journal",
issn = "0892-6638",
publisher = "FASEB",
number = "12",

}

TY - JOUR

T1 - Long-acting antituberculous therapeutic nanoparticles target macrophage endosomes

AU - Edagwa, Benson J

AU - Guo, Dongwei

AU - Puligujja, Pavan

AU - Chen, Han

AU - McMillan, JoEllyn M

AU - Liu, Xinming

AU - Gendelman, Howard Eliot

AU - Narayanasamy, Prabagaran

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Eradication of Mycobacterium tuberculosis (MTB) infection requires daily administration of combinations of rifampin (RIF), isoniazid [isonicotinylhydrazine (INH)], pyrazinamide, and ethambutol, among other drug therapies. To facilitate and optimize MTB therapeutic selections, a mononuclear phagocyte (MP; monocyte, macrophage, and dendritic cell)-targeted drug delivery strategy was developed. Long-acting nanoformulations of RIF and an INH derivative, pentenyl-INH (INHP), were prepared, and their physicochemical properties were evaluated. This included the evaluation of MP particle uptake and retention, cell viability, and antimicrobial efficacy. Drug levels reached 6 μg/10 6 cells in human monocyte-derived macrophages (MDMs) for nanoparticle treatments compared with 0.1 μg/10 6 cells for native drugs. High RIF and INHP levels were retained in MDM for >15 d following nanoparticle loading. Rapid loss of native drugs was observed in cells and culture fluids within 24 h. Antimicrobial activities were determined against Mycobacterium smegmatis (M. smegmatis). Coadministration of nanoformulated RIF and INHP provided a 6-fold increase in therapeutic efficacy compared with equivalent concentrations of native drugs. Notably, nanoformulated RIF and INHP were found to be localized in recycling and late MDM endosomal compartments. These were the same compartments that contained the pathogen. Our results demonstrate the potential of antimicrobial nanomedicines to simplify MTB drug regimens.

AB - Eradication of Mycobacterium tuberculosis (MTB) infection requires daily administration of combinations of rifampin (RIF), isoniazid [isonicotinylhydrazine (INH)], pyrazinamide, and ethambutol, among other drug therapies. To facilitate and optimize MTB therapeutic selections, a mononuclear phagocyte (MP; monocyte, macrophage, and dendritic cell)-targeted drug delivery strategy was developed. Long-acting nanoformulations of RIF and an INH derivative, pentenyl-INH (INHP), were prepared, and their physicochemical properties were evaluated. This included the evaluation of MP particle uptake and retention, cell viability, and antimicrobial efficacy. Drug levels reached 6 μg/10 6 cells in human monocyte-derived macrophages (MDMs) for nanoparticle treatments compared with 0.1 μg/10 6 cells for native drugs. High RIF and INHP levels were retained in MDM for >15 d following nanoparticle loading. Rapid loss of native drugs was observed in cells and culture fluids within 24 h. Antimicrobial activities were determined against Mycobacterium smegmatis (M. smegmatis). Coadministration of nanoformulated RIF and INHP provided a 6-fold increase in therapeutic efficacy compared with equivalent concentrations of native drugs. Notably, nanoformulated RIF and INHP were found to be localized in recycling and late MDM endosomal compartments. These were the same compartments that contained the pathogen. Our results demonstrate the potential of antimicrobial nanomedicines to simplify MTB drug regimens.

KW - Immunoisolation

KW - MDM

KW - Mycobacterium smegmatis

KW - Mycobacterium tuberculosis

KW - Subcellular trafficking

UR - http://www.scopus.com/inward/record.url?scp=84919784607&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919784607&partnerID=8YFLogxK

U2 - 10.1096/fj.14-255786

DO - 10.1096/fj.14-255786

M3 - Article

VL - 28

SP - 5071

EP - 5082

JO - FASEB Journal

JF - FASEB Journal

SN - 0892-6638

IS - 12

ER -